InsiderTrades.com logo
Bill Gates’s Next Big AI Bet: Stargate
From Brownstone Research   |   Ad
In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.
I believe we are about to do it again with this new AI project called Stargate
Justin D. Gover net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Justin Gover Biography and Net Worth

CEO of GW Pharmaceuticals
Justin Gover is the founding Chief Executive Officer of GW Pharmaceuticals plc, the parent company of Greenwich Biosciences. He has served in this role since January 1999. Throughout this 19-year period, Mr. Gover has served on GW’s Board of Directors.

What is Justin D. Gover's net worth?

The estimated net worth of Justin D. Gover is at least $108.41 million as of November 17th, 2020. Mr. Gover owns 495,113 shares of GW Pharmaceuticals stock worth more than $108,409,942 as of November 16th. This net worth approximation does not reflect any other investments that Mr. Gover may own. Additionally, Mr. Gover receives a salary of $1,190,000.00 as CEO at GW Pharmaceuticals. Learn More about Justin D. Gover's net worth.

How old is Justin D. Gover?

Mr. Gover is currently 50 years old. There are 5 older executives and no younger executives at GW Pharmaceuticals. Learn More on Justin D. Gover's age.

What is Justin D. Gover's salary?

As the CEO of GW Pharmaceuticals plc, Mr. Gover earns $1,190,000.00 per year. Learn More on Justin D. Gover's salary.

How do I contact Justin D. Gover?

The corporate mailing address for Mr. Gover and other GW Pharmaceuticals executives is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. GW Pharmaceuticals can also be reached via phone at 44-12-2326-6800 and via email at [email protected]. Learn More on Justin D. Gover's contact information.

Has Justin D. Gover been buying or selling shares of GW Pharmaceuticals?

Justin D. Gover has not been actively trading shares of GW Pharmaceuticals during the past quarter. Most recently, Justin D. Gover sold 42,708 shares of the business's stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $10.03, for a transaction totalling $428,361.24. Following the completion of the sale, the chief executive officer now directly owns 495,113 shares of the company's stock, valued at $4,965,983.39. Learn More on Justin D. Gover's trading history.

Who are GW Pharmaceuticals' active insiders?

GW Pharmaceuticals' insider roster includes Cabot Brown (Director), Adam George (Insider), Justin Gover (CEO), Geoffrey Guy (Chairman), Volker Knappertz (Director), Douglas Snyder (Insider), and Christopher Tovey (COO). Learn More on GW Pharmaceuticals' active insiders.

Justin D. Gover Insider Trading History at GW Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2020Sell42,708$10.03$428,361.24495,113View SEC Filing Icon  
11/12/2020Sell64,308$10.01$643,723.08459,653View SEC Filing Icon  
11/9/2020Sell7,200$10.00$72,000.00459,653View SEC Filing Icon  
2/26/2020Sell12,000$9.05$108,600.00554,045View SEC Filing Icon  
12/17/2019Sell5,340$9.17$48,967.80568,865View SEC Filing Icon  
5/28/2019Sell202,224$15.24$3,081,893.76743,765View SEC Filing Icon  
3/15/2019Sell23,400$14.01$327,834.00View SEC Filing Icon  
2/26/2019Sell11,112$12.45$138,344.40392,885View SEC Filing Icon  
2/13/2019Sell22,620$12.50$282,750.00370,445View SEC Filing Icon  
1/2/2019Sell22,620$8.33$188,424.60View SEC Filing Icon  
See Full Table

Justin D. Gover Buying and Selling Activity at GW Pharmaceuticals

This chart shows Justin D Gover's buying and selling at GW Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

GW Pharmaceuticals Company Overview

GW Pharmaceuticals logo
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $218.96
Low: $218.96
High: $218.96

50 Day Range

MA: $218.59
Low: $216.90
High: $219.28

2 Week Range

Now: $218.96
Low: $87.07
High: $219.57

Volume

N/A

Average Volume

899,771 shs

Market Capitalization

$6.86 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.15
Bill Gates’s Next Big AI Bet: Stargate
From Brownstone Research   |   Ad
In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.
I believe we are about to do it again with this new AI project called Stargate